Amikacin - PubMed (original) (raw)

Book

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.

2023 Jul 17.

Affiliations

Free Books & Documents

Book

Amikacin

Omeed Sizar et al.

Free Books & Documents

Excerpt

Amikacin is an antimicrobial with activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. It also has excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia sp. and some Mycobacterium spp. (M. avium-intracellulare, M. chelonae, and M. fortuitum). Unlike gentamicin, amikacin does not provide synergistic activity against Enterococcus faecium when combined with beta-lactam antibiotics. This activity covers amikacin, its mechanism, activity spectrum, and its place in an infectious disease regimen. Members of the interprofessional team need to review its indications, coverage, contraindications, and adverse event profile to optimally manage patients with infectious disease.

Copyright © 2025, StatPearls Publishing LLC.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Omeed Sizar declares no relevant financial relationships with ineligible companies.

Disclosure: Sajedur Rahman declares no relevant financial relationships with ineligible companies.

Disclosure: Vidya Sundareshan declares no relevant financial relationships with ineligible companies.

Sections

Similar articles

References

    1. Endo A, Nemoto A, Hanawa K, Maebayashi Y, Hasebe Y, Kobayashi M, Naito A, Kobayashi Y, Yamamoto S, Isobe K. Relationship between amikacin blood concentration and ototoxicity in low birth weight infants. J Infect Chemother. 2019 Jan;25(1):17-21. - PubMed
    1. Nolt VD, Pijut KD, Autry EB, Williams WC, Burgess DS, Burgess DR, Arora V, Kuhn RJ. Amikacin target achievement in adult cystic fibrosis patients utilizing Monte Carlo simulation. Pediatr Pulmonol. 2019 Jan;54(1):33-39. - PubMed
    1. Kulengowski B, Clark JA, Burgess DS. Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin. Diagn Microbiol Infect Dis. 2019 Apr;93(4):372-375. - PubMed
    1. Block M, Blanchard DL. StatPearls [Internet] StatPearls Publishing; Treasure Island (FL): 2023. Jul 17, Aminoglycosides. - PubMed
    1. Sturkenboom MGG, Simbar N, Akkerman OW, Ghimire S, Bolhuis MS, Alffenaar JC. Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment. Clin Infect Dis. 2018 Nov 28;67(suppl_3):S303-S307. - PubMed

Publication types

LinkOut - more resources